News

Newsletter

BPTO allows revision of the term adjustment of patents impacted by the DPC 5529

After judgment of the DPC 5529, the Federal Supreme Court decided that the provision of the Sole Paragraph of Article 40 of the Brazilian Patent Law, according to which patents of invention and utility model should be in force respectively for at least 10 and 7 years after granting, breaches the Brazilian Constitution. 
 
The Federal Supreme Court has also established about the modulation of effects of this decision, which will retroact: 
1) For patents related to pharmaceutical products and processes and equipment and/or materials for health use that are in force and have a term of protection of 10 or 7 years counted as from their granting; and 
2) For patents, in all technological areas, being challenged in lawsuits filed until April 7, 2021. 
By means of publication made in the Official Gazette (O.G.) No. 2633, of June 22, 2021, the Brazilian PTO communicated that, as of the publication of the adjustment of the patent protection term (decision code 16.3), the patent holder will have 60 days to request a review of the BPTO’s act. 
 
This opportunity was provided since, in specific cases, the applicability of the DPC 5529 decision from the BPTO side, based at the moment exclusively on international classifications and ANVISA’s prior consent, could impact patents whose subject matter would not be exclusively related to pharmaceutical products and processes and equipment and/or materials for health use. 
 
If there is interest in questioning the adjustment of a patent term, the holder must submit a petition to the BPTO, clarifying the reasons why such adjustment should not have occurred. The presented clarifications will be analyzed and, if considered pertinent, the patent term will be readjusted to the original term. If the clarifications are not considered pertinent the reduction of the patent term will be maintained and the rejection of the request will be notified in the Official Gazette. Appeals will still be available after this administrative act.   
If you need more information on this matter, please contact us at mail@kasznarleonardos.com or through your usual contact.
Back

Last related news

August 16, 2022

Brazilian National Health Surveillance Agency (ANVISA) decides to ban Carbendazim

On August 8th, 2022, during the 12th Extraordinary Public Meeting of DICOL, ANVISA’s Collegiate Board of Directors announced the completion of the toxicological Brazilian National Health Surveillance Agency (ANVISA) decides to ban Carbendazim

Ler notícia

July 19, 2022

Carbendazim toxicological revaluation about to be completed by ANVISA

In December 2019, ANVISA started the process of toxicological revaluation of the Active Ingredient (AI) Carbendazim, as signs of toxicity were identified Carbendazim toxicological revaluation about to be completed by ANVISA

Ler notícia

July 6, 2022

Compulsory license: patent owners in Brazil are under no obligation to provide know-how and raw materials

Good news for patent owners in Brazil: the National Congress has upheld the President’s veto n° 48/2021, which prevented those who had their Compulsory license: patent owners in Brazil are under no obligation to provide know-how and raw materials

  • Kasznar Leonardos
  • Ler notícia